Important: Enzalutamide 40 mg is an established strength used in prostate cancer treatment. However, the exact formulation must be verified because enzalutamide is available as both capsules and tablets in different markets.
Safety Warning: Enzalutamide may cause seizures, falls, fractures, hypertension, cardiovascular complications, and rare serious neurological reactions. It also has clinically important drug interactions. Treatment requires supervision by an oncology or urology specialist.
What Is Enzalutamide 40 mg?
Enzalutamide 40 mg is an oral hormonal anticancer medicine used to treat selected types of prostate cancer.
It belongs to a group of medicines called androgen receptor inhibitors.
Prostate cancer cells often depend on male hormones, particularly testosterone and dihydrotestosterone, to grow and survive.
These hormones activate androgen receptors inside prostate cancer cells.
Once activated, androgen receptors influence genes involved in cancer cell growth and survival.
Enzalutamide blocks androgen receptor signaling, helping reduce the ability of prostate cancer cells to respond to androgen stimulation.
Unlike medicines that primarily reduce testosterone production, enzalutamide acts directly on androgen receptor signaling.
It is used in several prostate cancer treatment settings, including metastatic and nonmetastatic disease.
Depending on the diagnosis, enzalutamide may be prescribed alongside androgen deprivation therapy.
It may also be used in selected patients with nonmetastatic castration-sensitive prostate cancer and high-risk biochemical recurrence, according to applicable prescribing criteria.
Enzalutamide is not conventional cytotoxic chemotherapy.
It is a targeted hormonal anticancer therapy intended to control disease progression and improve clinical outcomes in appropriately selected patients.
Common Reasons for Prescribing Enzalutamide 40 mg
- Metastatic castration-resistant prostate cancer
- Nonmetastatic castration-resistant prostate cancer
- Metastatic castration-sensitive prostate cancer
- Selected nonmetastatic castration-sensitive prostate cancer
- Prostate cancer progression despite testosterone suppression
- Androgen receptor signaling inhibition
- Advanced prostate cancer management
- Metastatic prostate cancer treatment
- Hormonal anticancer therapy
- Specialist-directed prostate cancer treatment
- Reduction of prostate cancer progression risk
- Management of selected high-risk biochemical recurrence
Important: Enzalutamide is not appropriate for every patient with prostate cancer. Treatment eligibility depends on disease stage, metastatic status, hormone sensitivity, previous treatments, and the applicable prescribing information.
How Does Enzalutamide 40 mg Work?
1. Blocks Androgen Receptors
Enzalutamide binds to androgen receptors and inhibits their activation by androgen hormones.
2. Prevents Androgen Receptor Signaling
It interferes with the signaling processes that allow prostate cancer cells to respond to testosterone and dihydrotestosterone.
3. Inhibits Androgen Receptor Nuclear Translocation
Enzalutamide reduces the movement of activated androgen receptors into the cell nucleus.
4. Interferes With DNA Binding
It inhibits androgen receptor interactions with DNA that regulate cancer-related gene expression.
5. Reduces Androgen-Dependent Gene Expression
Blocking androgen receptor signaling reduces the expression of genes involved in prostate cancer growth.
6. Suppresses Cancer Cell Proliferation
Enzalutamide can reduce androgen-driven proliferation of susceptible prostate cancer cells.
7. Helps Delay Disease Progression
By inhibiting androgen signaling, the medicine may delay progression in selected prostate cancer settings.
8. Supports Treatment of Castration-Resistant Disease
Some prostate cancers continue using androgen receptor signaling despite low testosterone levels.
Enzalutamide can inhibit this signaling pathway.
9. Supports Treatment of Castration-Sensitive Disease
Enzalutamide may also be used in selected hormone-sensitive prostate cancer settings.
10. Improves Clinical Outcomes in Eligible Patients
Clinical studies have demonstrated benefits in disease progression and survival outcomes in specific approved prostate cancer populations.
Important: Enzalutamide does not guarantee tumor elimination or a cure. Response varies depending on disease characteristics and individual factors.
Uses of Enzalutamide 40 mg
1. Metastatic Castration-Resistant Prostate Cancer
Enzalutamide is used in patients with metastatic prostate cancer that continues to progress despite castrate testosterone levels.
2. Nonmetastatic Castration-Resistant Prostate Cancer
It is used in selected patients with castration-resistant prostate cancer without detectable distant metastases.
3. Metastatic Castration-Sensitive Prostate Cancer
Enzalutamide may be prescribed for metastatic prostate cancer that remains sensitive to androgen deprivation.
4. Nonmetastatic Castration-Sensitive Prostate Cancer
In certain markets, enzalutamide is approved for patients with nonmetastatic castration-sensitive prostate cancer who have biochemical recurrence at high risk for metastasis.
5. Advanced Prostate Cancer
Enzalutamide is an established treatment option for selected advanced prostate cancer cases.
6. Prostate Cancer Progression Management
The medicine may delay disease progression by inhibiting androgen receptor activity.
7. Androgen Receptor Inhibition
Enzalutamide targets a major signaling pathway involved in prostate cancer development and progression.
8. Hormonal Anticancer Therapy
It may be included in a broader endocrine treatment plan.
9. Treatment Alongside Androgen Deprivation Therapy
In many approved settings, enzalutamide is administered while testosterone suppression is maintained.
10. Management of High-Risk Biochemical Recurrence
Certain eligible patients with high-risk biochemical recurrence may receive enzalutamide according to local approvals and specialist recommendations.
11. Metastatic Disease Control
Enzalutamide may help delay progression of metastatic prostate cancer.
12. Specialist-Directed Long-Term Oncology Treatment
Treatment may continue while clinical benefit is maintained and adverse effects remain acceptable.
Important: Enzalutamide is not a general treatment for all cancers, benign prostate enlargement, urinary infections, or erectile dysfunction.
Enzalutamide 40 mg Dosage and Administration
Enzalutamide dosing must be determined by the treating oncology or urology specialist.
General Dosage Information
| Dosage Information | Details |
|---|---|
| Active Ingredient | Enzalutamide |
| Unit Strength | 40 mg |
| Commonly Recommended Adult Dose | 160 mg once daily |
| Number of 40 mg Units at 160 mg | 4 capsules or tablets |
| Administration Route | Oral |
| With Food | May be taken with or without food |
| Treatment Frequency | Once daily |
| Dose Adjustments | May be required for adverse reactions or drug interactions |
| Treatment Duration | Determined by clinical response and tolerability |
| Medical Supervision | Mandatory |
Important: The standard 160 mg daily regimen is general prescribing information, not a personalized instruction to take four units. Some patients require dose interruption or reduction.
How to Take Enzalutamide 40 mg
- Take enzalutamide exactly as prescribed.
- Confirm the strength and formulation before starting treatment.
- Take the prescribed dose once daily.
- Take the medicine at approximately the same time each day.
- It may be taken with or without food.
- Swallow the capsules or tablets whole with water.
- Do not crush or chew the medicine.
- Do not open or dissolve capsules.
- Follow any formulation-specific instructions regarding splitting tablets.
- Do not increase the prescribed dose.
- Do not stop treatment without discussing it with the prescribing specialist.
- Inform the healthcare team about all medicines and supplements.
- Attend scheduled oncology appointments.
- Report seizures, severe headaches, chest pain, or neurological symptoms immediately.
- Follow recommendations for fall and fracture prevention.
- Continue any prescribed androgen deprivation therapy unless the specialist instructs otherwise.
Can Enzalutamide Be Taken With Food?
Yes.
Enzalutamide may generally be taken with or without food.
What If a Dose Is Missed?
If a dose is missed, take it when remembered on the same day.
If an entire day is missed, resume the prescribed dose the following day.
Do not take two doses together to compensate for a missed dose.
What If Too Much Enzalutamide Is Taken?
Seek immediate medical advice.
An overdose may increase the risk of serious adverse effects, including seizures.
Can Enzalutamide Be Stopped Suddenly?
Treatment interruption may be necessary because of serious side effects.
However, patients should not independently discontinue treatment without consulting their oncology team, except when urgent medical care is required.
How Long Does Enzalutamide 40 mg Take to Work?
Enzalutamide begins inhibiting androgen receptor signaling after administration.
However, clinical response is assessed over weeks or months.
Oncologists may evaluate treatment using:
- Prostate-specific antigen (PSA) levels
- Testosterone levels when appropriate
- CT scans
- MRI scans
- Bone scans
- Clinical examinations
- Assessment of cancer-related symptoms
- Evaluation of adverse effects
- Overall disease progression
PSA changes may provide useful information, but PSA alone does not determine treatment success.
Important: Enzalutamide does not guarantee immediate symptom relief, complete tumor regression, or a cure.
Common Side Effects
Possible side effects include:
- Fatigue
- Weakness
- Hot flashes
- High blood pressure
- Joint pain
- Back pain
- Muscle pain
- Headache
- Dizziness
- Reduced appetite
- Weight loss
- Diarrhea
- Constipation
- Sleep disturbances
- Falls
- Swelling
- Cognitive or concentration difficulties
Patients should report persistent or worsening symptoms to their healthcare team.
Potentially Harmful Effects & Serious Health Risks
1. Seizures
Enzalutamide may increase the risk of seizures.
Patients with seizure disorders or other predisposing conditions require careful assessment.
2. Posterior Reversible Encephalopathy Syndrome
A rare neurological condition called posterior reversible encephalopathy syndrome (PRES) may occur.
Symptoms can include severe headache, confusion, seizures, and visual disturbances.
3. Ischemic Heart Disease
Enzalutamide may increase the risk of ischemic heart disease.
4. Severe Hypertension
Blood pressure may increase during treatment.
5. Falls
Dizziness, weakness, and treatment-related effects may increase the risk of falls.
6. Bone Fractures
Fractures have been reported in patients receiving enzalutamide.
7. Cognitive Impairment
Some patients may experience problems with memory, concentration, or attention.
8. Severe Fatigue
Fatigue may interfere with daily activities and treatment tolerance.
9. Hypersensitivity Reactions
Allergic reactions, including swelling of the face, tongue, or throat, may occur.
10. Severe Skin Reactions
Rare serious skin reactions, including severe cutaneous adverse reactions, have been reported.
11. Drug Interaction-Related Treatment Failure
Enzalutamide can reduce exposure to several other medicines by inducing drug-metabolizing enzymes.
12. Drug Interaction-Related Toxicity
Certain medicines can increase enzalutamide exposure and may require dose adjustment.
13. Cardiovascular Complications
Patients with pre-existing cardiovascular disease may require additional monitoring.
14. Reproductive Toxicity
Enzalutamide may cause fetal harm if exposure occurs during pregnancy.
15. Reduced Fertility
Enzalutamide may impair male fertility.
16. Severe Neurological Symptoms
New seizures, significant confusion, or visual changes require urgent assessment.
Emergency warning: Seek immediate medical attention for seizures, chest pain, sudden weakness, severe headache with confusion, significant visual disturbances, or swelling of the face or throat.
Contraindications & Safety Precautions
1. Hypersensitivity
Do not use enzalutamide if a serious allergic reaction to the medicine or its ingredients has occurred.
2. Seizure Disorders
Patients with a history of seizures require careful risk assessment.
3. Neurological Conditions
Brain injury, certain neurological disorders, and medicines that lower the seizure threshold may increase seizure risk.
4. Cardiovascular Disease
Patients with heart disease require appropriate clinical assessment.
5. Hypertension
Blood pressure should be monitored during treatment.
6. Fall Risk
Patients with dizziness, weakness, or mobility difficulties may require fall-prevention measures.
7. Bone Health
Bone health should be assessed when clinically appropriate.
8. Liver Impairment
Patients with significant liver impairment should be evaluated according to the applicable prescribing information.
9. Kidney Impairment
Patients with severe renal impairment require careful clinical assessment because available data may be limited.
10. Pregnancy
Enzalutamide is not indicated for use in women and may cause fetal harm.
11. Contraception
Male patients with partners who can become pregnant should use effective contraception during treatment and for three months after the final dose.
12. Breastfeeding
Enzalutamide is not indicated for use in women. Human milk exposure data are unavailable.
13. Fertility
Enzalutamide may impair male fertility.
14. Pediatric Use
Safety and effectiveness in pediatric patients have not been established.
15. Older Adults
Older patients may require additional monitoring for falls, fractures, cardiovascular effects, and treatment tolerance.
16. Drug Interactions
Enzalutamide has important interactions because it is metabolized by CYP enzymes and can induce several drug-metabolizing pathways.
Potentially important interactions include:
- Gemfibrozil: A strong CYP2C8 inhibitor that may increase enzalutamide exposure.
- Rifampin: May alter enzalutamide exposure through enzyme induction.
- Carbamazepine: May reduce exposure to certain medicines and complicate treatment.
- Phenytoin: May interact through enzyme-inducing pathways.
- Warfarin: Enzalutamide may reduce warfarin exposure; INR monitoring is important.
- Certain Anticoagulants: Exposure may be altered, requiring clinical review.
- Certain Antiepileptic Medicines: May interact with enzalutamide or affect seizure risk.
- Certain Cardiovascular Medicines: Enzalutamide may reduce concentrations of CYP-metabolized drugs.
- Certain Antifungal Medicines: May alter drug exposure.
- Other CYP3A4, CYP2C9, or CYP2C19 Substrates: May require monitoring or alternative treatment.
17. Strong CYP2C8 Inhibitors
Concomitant use may require dose modification.
18. Strong CYP3A4 Inducers
Strong enzyme inducers may alter enzalutamide exposure and should be reviewed carefully.
19. Driving and Machinery
Patients experiencing dizziness, fatigue, or neurological symptoms should avoid driving or operating machinery.
20. Medical Monitoring
Healthcare professionals may monitor:
- PSA levels
- Testosterone levels when appropriate
- Blood pressure
- Cardiovascular symptoms
- Neurological symptoms
- Seizure risk
- Falls
- Bone health
- Fracture risk
- Fatigue
- Cognitive changes
- Treatment adherence
- Drug interactions
- Disease progression
- Treatment tolerability
- Need for dose adjustment
Advantages
- Oral androgen receptor inhibitor.
- Established role in prostate cancer treatment.
- Targets androgen receptor signaling.
- Approved for multiple prostate cancer settings.
- Used in metastatic castration-resistant disease.
- Used in nonmetastatic castration-resistant disease.
- Used in metastatic castration-sensitive disease.
- Approved for selected high-risk biochemical recurrence.
- May delay prostate cancer progression.
- May improve survival outcomes in eligible patients.
- Once-daily administration.
- May be taken with or without food.
- Available in 40 mg strength.
- Can be combined with androgen deprivation therapy when indicated.
Disadvantages / Limitations
- May cause severe fatigue.
- May increase seizure risk.
- May cause dizziness.
- May cause hypertension.
- May increase fall risk.
- May increase fracture risk.
- May cause joint pain.
- May cause back pain.
- May cause hot flashes.
- May affect concentration.
- May cause headaches.
- May cause diarrhea.
- May cause constipation.
- May increase cardiovascular risk.
- May cause serious neurological complications.
- May cause hypersensitivity reactions.
- Has significant drug interactions.
- May impair fertility.
- Requires specialist supervision.
- Does not guarantee a cure.
- Is not appropriate for every prostate cancer patient.
Important Notes
Generic Name: Enzalutamide.
Product Name: Enzalutamide 40 mg.
Strength: 40 mg per capsule or tablet.
Drug Class: Androgen Receptor Inhibitor.
Therapeutic Category: Oncology / Hormonal Anticancer Medicine.
Primary Use: Selected types of prostate cancer.
Mechanism: Inhibition of androgen receptor signaling.
Administration Route: Oral.
Reference Brand: Xtandi.
Commonly Recommended Adult Dose: 160 mg once daily.
Major Warning: Risk of seizures, cardiovascular complications, falls, and fractures.
Common Side Effects: Fatigue, hot flashes, joint pain, and hypertension.
Serious Risks: Seizures, PRES, ischemic heart disease, and fractures.
Pregnancy: May cause fetal harm; not indicated for use in women.
Contraception: Effective contraception is recommended for male patients with partners who can become pregnant during treatment and for three months afterward.
Pediatric Use: Not established.
Monitoring: PSA, blood pressure, neurological symptoms, cardiovascular health, and treatment response.
Prescription Status: Prescription-Only Anticancer Medicine.
Storage: Follow manufacturer instructions.
Frequently Asked Questions
1. What is Enzalutamide 40 mg used for?
Enzalutamide is used to treat selected types of prostate cancer, including metastatic and nonmetastatic castration-resistant disease and certain castration-sensitive disease settings.
2. What is the generic name of Xtandi?
The generic name is enzalutamide.
3. Is Enzalutamide chemotherapy?
No. Enzalutamide is a hormonal anticancer medicine known as an androgen receptor inhibitor.
4. How does Enzalutamide work?
It blocks androgen receptor signaling that contributes to prostate cancer growth.
5. Is Enzalutamide used for metastatic prostate cancer?
Yes. It is used in selected patients with metastatic prostate cancer.
6. Can Enzalutamide be used for nonmetastatic prostate cancer?
Yes. It is approved for certain nonmetastatic prostate cancer settings.
7. What is the usual Enzalutamide dose?
The commonly recommended adult dose is 160 mg once daily, subject to specialist assessment.
8. How many Enzalutamide 40 mg capsules make 160 mg?
Four 40 mg capsules contain 160 mg of enzalutamide. The prescribed dose must still be confirmed by the treating specialist.
9. Can Enzalutamide be taken with food?
Yes. It may generally be taken with or without food.



































































Zohar (verified owner) –
Viral Care is a game-changer for my immune support.
Owen (verified owner) –
Helped me recover faster from viral infections, amazing product!